Morgan Stanley’s HUMANIGEN, INC. HGEN Stock Holding History

Morgan Stanley’s Portfolio HGEN Stock Details HGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-62,003	Closed	-$9.45K	–	7822
2023 Q2	$9.45K	Sell	62,003 -1,211	-2%	-$188	﹤0.01%	6834
2023 Q1	$9.07K	Sell	63,214 -39,120	-38%	-$6.26K	﹤0.01%	6910
2022 Q4	$12.3K	Buy	102,334 +33,167	+48%	+$4.79K	﹤0.01%	6867
2022 Q3	$12K	Sell	69,167 -371,324	-84%	-$200K	﹤0.01%	7024
2022 Q2	$779K	Buy	440,491 +79,005	+22%	+$177K	﹤0.01%	5176
2022 Q1	$1.09M	Sell	361,486 -34,322	-9%	-$91.8K	﹤0.01%	4933
2021 Q4	$1.47M	Buy	395,808 +305,712	+339%	+$1.79M	﹤0.01%	4805
2021 Q3	$533K	Sell	90,096 -38,745	-30%	-$544K	﹤0.01%	5456
2021 Q2	$2.24M	Buy	128,841 +122,349	+1,885%	+$2.23M	﹤0.01%	4539
2021 Q1	$124K	Sell	6,492 -10,035	-61%	-$183K	﹤0.01%	5900
2020 Q4	$289K	Buy	16,527 +15,278	+1,223%	+$183K	﹤0.01%	5394
2020 Q3	$13K	Buy	+1,249	New	+$12.8K	﹤0.01%	6194

Other funds holding HGEN

TCM

Triumph Capital Management Denver, Colorado $491M AUM 12.29% 1-Year Est. Return

DWP

Daymark Wealth Partners Cincinnati, Ohio $3.18B AUM 23.46% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Morgan Stanley's HGEN Position: Q3 2023 in Review

Morgan Stanley sold out of HUMANIGEN, INC. (HGEN) in Q3 2023, closing a stake of 62,003 shares — an estimated $9.45K sold.

Morgan Stanley first reported a position in HGEN in Q3 2020 and held it in 12 quarters. The position peaked at $2.24M in Q2 2021. 3 funds tracked by Wall St. Rank hold HGEN as of Q3 2023.

Morgan Stanley reported no remaining HUMANIGEN, INC. position as of Q3 2023 after selling out during the quarter.
Morgan Stanley sold 62,003 HUMANIGEN, INC. shares in Q3 2023, an estimated $9.45K.
Morgan Stanley first reported a position in HUMANIGEN, INC. in Q3 2020 and held it in 12 quarters.
Morgan Stanley's HUMANIGEN, INC. position peaked at $2.24M in Q2 2021.
3 funds tracked by Wall St. Rank held HUMANIGEN, INC. as of Q3 2023.

Based on Morgan Stanley's 13F filing for Q3 2023, filed 15 Nov 2023.